UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006742
Receipt number R000007966
Scientific Title Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II study
Date of disclosure of the study information 2011/11/20
Last modified on 2021/05/25 15:54:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II study

Acronym

Efficacy and Safety study of adjuvant therapy with XELOX for the Japanese patient with StageIII curative resection Colon cancer

Scientific Title

Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer -Phase II study

Scientific Title:Acronym

Efficacy and Safety study of adjuvant therapy with XELOX for the Japanese patient with StageIII curative resection Colon cancer

Region

Japan


Condition

Condition

Colon cancer

Classification by specialty

Gastroenterology Hematology and clinical oncology Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Efficacy and Safety study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for the Japanese patient with Stage III curative resection Colon cancer

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

3 year disease free survival

Key secondary outcomes

Completion rate of treatment,Safety, Duration of administration of oxaliplatin, Incidence of Peripheral neuropathy and hand foot syndrome, Incidence and Survival of hand foot syndrome, dose intensity,Efficacy of Stage IIIa, IIIb


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Adjuvant chemotherapy with capecitabine plus oxaliplatin

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Histologically proved colon cancer(adenocarcinoma)
2) Stage III colon cancer or RS
3) >=D2 lymph node dissection
4) Pathological curability is A
5) >=20years-old
6) ECOG performance status 0-1
7) No prior chemotherapy or radiotherapy
8) Enough oral food intake possible
9) Adequate organ function
10) Able to start within 8 weeks after surgery
11) Written informed consent

Key exclusion criteria

1) Present with diarrhea
2) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ
3) CTCAE v4.0>Grade1 of peripheral neuropathy
4) regular use of insulin
5) uncontrollable congestive heart failure, angina,hypertension, arrhythmia
6) Severe mental disease
7) active infection
8) Pregnant or breast-feeding women
9) Woman might be pregnant
10) Inadequate physical condition, as diagnosed by primary physician

Target sample size

140


Research contact person

Name of lead principal investigator

1st name katsuki
Middle name
Last name Danno

Organization

Minoh City Hospital

Division name

Department of Surgery

Zip code

562-0014

Address

5-7-1 Kayano, Minoh, Osaka 562-0014, Japan

TEL

072-728-2001

Email

k.danno@minoh-hp.jp


Public contact

Name of contact person

1st name Mamoru
Middle name
Last name Uemura

Organization

Osaka University Graduate School of Medicine

Division name

Department of Surgery

Zip code

565-0871

Address

2-2 Yamadaoka, Suita, Osaka 565-0871,Japan

TEL

06-6879-3251

Homepage URL


Email

muemura@gesurg.med.osaka-u.ac.jp


Sponsor or person

Institute

Multicenter Study Group of Osaka (MCSGO), Colorectal Cancer Treatment Group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The ethics committee of Osaka University

Address

2-15 Yamadaoka Suita-city Osaka,Japan

Tel

06-6879-5685

Email

rinri@hp-crc.med.osaka-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 11 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

195

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 11 Month 09 Day

Date of IRB

2011 Year 11 Month 09 Day

Anticipated trial start date

2011 Year 11 Month 10 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 11 Month 17 Day

Last modified on

2021 Year 05 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007966


Research Plan
Registered date File name
2016/07/06 StageⅢ結腸癌治癒切除例に対する術後補助化学療法XELOX療法の有効性・安全性の検討-PhaseⅡ試験-.zip

Research case data specifications
Registered date File name

Research case data
Registered date File name